Similar therapeutic serum levels attained with emulsified and oil‐based preparations of coenzyme Q₁₀

Abstract

Studies of the therapeutic efficacy of coenzyme Q10 (CoQ10) have been confounded by the variable bioavailability of numerous CoQ10 preparations. The aims of the present study were to determine the early serum levels attained by two different preparations of CoQ10, a soybean oil-based preparation and a complex micelle emulsion and to assess whether these preparations of oral CoQ10 influence plasma lipid profiles. Twelve healthy individuals received 300 mg CoQ10 daily of either preparation for 7 days in a double-blind cross-over design with a 21-day washout period. Blood samples to determine serum levels of CoQ10 and lipids were taken at baseline, after 24 h and 7 days. Both preparations induced significant increases in serum CoQ10 levels at 24 h and 7 days. These were for soy oil: baseline 0.27 +/- 0.03 mol/L, 24 h 0.50 +/- 0.04 mol/L (180%) and 7 days 0.80 +/- 0.05 mol/L (291%), mean +/- SEM: for emulsion: baseline 0.29 +/- 0.03 mol/L, 24 h 0.45 +/- 0.03 mol/L (150%) and 7 days 0.79 +/- 0.06 mol/L (270%). There were no significant differences between CoQ10 levels for the two preparations at either time point. There was no change in any of the serum lipids following the 7 days treatment. We conclude that administration of either a soy oil suspension or a complex emulsion of CoQ10 increases serum levels to the therapeutic range within 1 week.

Relative bioavailability of coenzyme Q10 formulation for paediatric individualized therapy

“…In spite of the suggestion of adapting different formulations over time proposed by some authors, our results are in agreement with Chopra et al . who found a 3.2‐fold increase in bioavailability with solubilized CoQ10 compared with an oil suspension and tablets after a 3‐week supplementation with 120 mg/day.…”

Bioavailability Assessment of Vitamin A Self-Nanoemulsified Drug Delivery Systems in Rats: A Comparative Study

“…It has been recognized that SNEDDS enhanced the bioavailability of several preparations in humans and animals with an increase in its in vitro drug release characteristics [15,16] . However, in some reports, the bioavailability has not increased even though the in vitro dissolution rate or emulsification rate has increased [17,18] . Although there are some reports about anaphylactic reactions to Cremophor, these reactions were observed during intravenous administration, but not during oral administration, based on cytotoxicity studies for SNEDDS oral formulations containing Cremophor [19,20] .…”

Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure

“…This particular formulation was selected because a previous study had shown a threefold increase in serum levels after only 1 week of therapy 21 . The colour‐matched placebo capsule was identical to the active capsule with the exception of the CoQ 10 .…”